I want to break down something critically important from the SELECT trial that I think gets lost in the media noise about "weight-loss drugs."
The SELECT trial enrolled 17,604 adults with established cardiovascular disease and BMI ≥27 but without diabetes. Semaglutide 2.4 mg weekly vs. placebo. Primary endpoint: time to first MACE (CV death, nonfatal MI, nonfatal stroke).[1]
"Semaglutide reduced the risk of MACE by 20% (HR 0.80; 95% CI, 0.72–0.90; P<0.001) over a mean follow-up of 39.8 months."
Here is the key finding that everyone needs to internalize: the cardiovascular benefit was observed early — within the first few months — before clinically significant weight loss had occurred. The Kaplan-Meier curves separated by approximately month 4-6. Median weight loss at that point was only ~5-6%.
Furthermore, mediation analyses showed that weight loss accounted for only a fraction of the MACE reduction. The anti-inflammatory and direct vascular effects appear to be driving much of the benefit.
This has massive implications for how we conceptualize GLP-1 receptor agonists. They are not merely "weight loss drugs with cardiac side-benefits." They are cardiovascular drugs that also happen to cause weight loss.
[1] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
This is exactly right and it mirrors what we saw in SUSTAIN-6 for the T2DM population. In SUSTAIN-6, semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% (HR 0.74; 95% CI, 0.58–0.95) in patients with type 2 diabetes at high CV risk.[1]
The consistency across diabetic and non-diabetic populations strongly argues for a class effect that goes beyond glycemic control or weight loss. We're likely looking at:
- Direct anti-atherosclerotic effects on vascular endothelium
- Reduction in systemic inflammation (hsCRP reductions of 30-40%)
- Improvements in endothelial function and arterial stiffness
- Favorable effects on platelet aggregation
The mechanistic story is becoming very compelling.
[1] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
Let me lay out the timeline data from SELECT because it really drives the point home:
| Timepoint | Median Weight Loss (%) | MACE HR (approx.) | Curve Separation |
|---|---|---|---|
| Month 3 | ~3.5% | ~0.88 | Beginning to separate |
| Month 6 | ~6.0% | ~0.82 | Clear separation |
| Month 12 | ~8.5% | ~0.80 | Sustained divergence |
| Month 24 | ~9.4% | ~0.80 | Persistent benefit |
| Month 40 (end) | ~9.4% | 0.80 (final) | 20% relative risk reduction |
Notice that weight loss essentially plateaus after month 12-16, yet the CV benefit remains constant. If weight loss were the primary mediator, you'd expect the hazard ratio to improve proportionally with weight — but it doesn't. The benefit was largely "locked in" early.
The NNT (number needed to treat) over 40 months was approximately 67 to prevent one MACE event. For context, that's competitive with high-intensity statin therapy.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAs a patient with prior NSTEMI and BMI of 31, this trial literally changed my treatment plan. My cardiologist added semaglutide 2.4 mg not primarily for weight loss but as a secondary prevention agent alongside my statin, ACEi, and aspirin.
8 months in, my labs tell the story:
| Marker | Baseline | 8 Months |
|---|---|---|
| hsCRP (mg/L) | 4.8 | 1.2 |
| LDL-C (mg/dL) | 78 (on statin) | 64 |
| Triglycerides (mg/dL) | 198 | 112 |
| A1C (%) | 5.9 | 5.2 |
| Systolic BP (mmHg) | 138 | 118 |
| Weight (lbs) | 224 | 198 |
The hsCRP drop is what excites my cardiologist the most. He says that inflammatory reduction probably matters more for my plaque stability than the 26 lbs I've lost.
Your cardiologist is spot on. The CANTOS trial demonstrated that reducing inflammation (via canakinumab targeting IL-1β) lowered MACE risk independent of LDL reduction. hsCRP is not just a bystander marker — it reflects the inflammatory milieu driving plaque vulnerability.
What SELECT shows is that semaglutide may be delivering some of that anti-inflammatory benefit as a "bonus" on top of metabolic improvements. Your hsCRP dropping from 4.8 to 1.2 mg/L is a 75% reduction — that's clinically very meaningful.
I'd also point out that your triglyceride reduction (198 → 112) suggests improved hepatic insulin sensitivity and reduced VLDL production, which has downstream effects on atherogenic particle number. Have you had ApoB measured?